People · Operator
Named in public records as an officer, director or promoter · active 2019–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alto Neuroscience, Inc. | — | Biotechnology | Series C | $193.9M | $271.1M | 2019 |
Andrew Nixon Dreyfus at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew Nixon Dreyfus on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Hanley | 1 | 5 |
| Nicholas Smith | 1 | 5 |
| Aaron Weaver | 1 | 3 |
| Gwill C. York | 1 | 1 |
| Husseini Nixon Manji | 1 | 1 |
| Christopher Nixon Cox | 1 | 1 |
| Raymond Nixon Sanchez | 1 | 1 |
| Michael Nixon Liang | 1 | 1 |
| Po Yu (Jeff) Chen | 1 | 1 |
| Chris Nixon Dimitropoulos | 1 | 1 |
| Adam Savitz | 1 | 1 |
| Gwill York | 1 | 1 |
| Amit Etkin | 1 | 1 |
| Nicholas C. Smith | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.